News | Published:

Industry pursues co-stimulatory receptor immunomodulators to treat cancer

Nature Biotechnology volume 31, pages 181183 (2013) | Download Citation

  • A Corrigendum to this article was published on 10 June 2013

This article has been updated

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 03 May 2013

    In the version of this article initially published, the experimental drug nivolumab was incorrectly designated BMS-936588. The correct designation is BMS-936558. The error has been corrected in the HTML and PDF versions of the article.

Author information


  1. Dublin

    • Cormac Sheridan


  1. Search for Cormac Sheridan in:

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing